Skip to main content
Swing Capital

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523Pharma

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

₹5,435
52W: ₹4716 — ₹5934
PE 29.3 · Book ₹1143 · +376% vs book
Market Cap₹64,987 Cr
Stock P/E29.3Price to Earnings
ROCE19.5%Return on Capital
ROE19.9%Return on Equity
Div. Yield0.83%Face Value ₹2

Strengths

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 34.6%

Weaknesses

  • −The company has delivered a poor sales growth of 5.71% over past five years.
  • −Tax rate seems low
  • −Promoter holding has decreased over last 3 years: -5.96%

Shareholding Pattern

Promoters51.2%
FIIs10.15%
DIIs21.39%
Public17.25%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters56.38%55.66%▼0.755.66%55.13%▼0.553.04%▼2.151.2%▼1.851.2%51.2%
FIIs8.69%9.02%▲0.310.14%▲1.19.4%▼0.79.11%▼0.39.47%▲0.49.97%▲0.510.15%▲0.2
DIIs18.56%19.21%▲0.718.01%▼1.219.42%▲1.421.8%▲2.421.93%▲0.121.54%▼0.421.39%▼0.1
Public16.37%16.12%▼0.316.19%▲0.116.05%▼0.116.05%17.39%▲1.317.3%▼0.117.25%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales2,6352,0092,3652,1272,3552,2872,0452,3722,5422,491
Expenses1,9801,5171,9581,5661,7141,6291,7481,7521,7711,802
Operating Profit655492408561640658297620771689
OPM %25%25%17%26%27%29%15%26%30%28%
Net Profit647504325583698723277656787622
EPS ₹54.0742.1727.1848.7858.3460.4823.1654.8865.852.03

AI Insights

Revenue Trend

TTM revenue at ₹9,450Cr, up 7.2% YoY. OPM at 25%.

Debt Position

Borrowings at ₹874Cr. Debt-to-equity ratio: 0.06x. Healthy balance sheet.

Capex Cycle

CWIP at ₹73Cr (5% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 21.39% (+5.05pp change). FIIs: 10.15% (+4.52pp change). Promoters hold 51.2%.

Margin & Efficiency

ROCE improving from 15% (Mar 2014) to 20% (Mar 2025). Working capital days: 128.

Valuation

PE 29.3x with 19.5% ROCE. Price is 376% above book value of ₹1,143. Dividend yield: 0.83%.

Recent Announcements